Nanoformulations of natural products for management of metabolic syndrome

References

• Tabatabaei-Malazy O, Larijani B, Abdollahi M. Targeting metabolic disorders by natural products. J Diabetes Metab Disord. 2015;14:57. doi:10.1186/s40200-015-0184-8
   Google Scholar
• McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20. doi:10.1016/j.clindermatol.2017.09.00429241747
   PubMed Web of Science ®Google Scholar
• Swarup S, Zeltser R. Metabolic syndrome In: StatPearls [internet]. StatPearls Publishing; 2018.
   Google Scholar
• Deen D. Metabolic syndrome: time for action. Am Fam Physician. 2004;69:12.
   Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014. doi:10.1155/2014/943162
   Google Scholar
• Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532–1555. doi:10.1016/j.addr.2006.09.00917092599
   PubMed Web of Science ®Google Scholar
• Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2012;64:37–48. doi:10.1016/j.addr.2012.09.013
   Web of Science ®Google Scholar
• Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am. 2007;91(6):1063–1077, viii. doi:10.1016/j.mcna.2007.06.01217964909
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet (London, England). 2005;365(9468):1415–1428. doi:10.1016/S0140-6736(05)66378-7
   PubMed Web of Science ®Google Scholar
• Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3(1):1–58. doi:10.1002/cphy.c11006223720280
   PubMed Web of Science ®Google Scholar
• Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507–520. doi:10.1152/physrev.00024.200617429039
   PubMed Web of Science ®Google Scholar
• Kim DH, Perdomo G, Zhang T, et al. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes. 2011;60(11):2763–2774. doi:10.2337/db11-054821940782
   PubMedGoogle Scholar
• Meyer MM, Levin K, Grimmsmann T, Beck-Nielsen H, Klein HH. Insulin signalling in skeletal muscle of subjects with or without type II-diabetes and first degree relatives of patients with the disease. Diabetologia. 2002;45(6):813–822. doi:10.1007/s00125-002-0830-912107725
   PubMedGoogle Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. doi:10.1038/nrm183716493415
   PubMed Web of Science ®Google Scholar
• Saha SS, Ghosh M. Antioxidant and anti-inflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes. Br J Nutr. 2012;108(6):974–983. doi:10.1017/S000711451100632522182422
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806. doi:10.1038/414799a11742412
   PubMed Web of Science ®Google Scholar
• Lizcano JM, Alessi DR. The insulin signalling pathway. Curr Biol. 2002;12(7):R236–R238.11937037
   PubMed Web of Science ®Google Scholar
• Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267–277. doi:10.1038/nrm78211994746
   PubMed Web of Science ®Google Scholar
• Patel TP, Rawal K, Bagchi AK, et al. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 2016;21(1):11–23. doi:10.1007/s10741-015-9515-626542377
   PubMed Web of Science ®Google Scholar
• Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215–225. doi:10.1177/175394471771137928639538
   PubMedGoogle Scholar
• Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med. 2000;247(4):425–431.10792555
   PubMed Web of Science ®Google Scholar
• Halpern A, Mancini MC, Magalhaes ME, et al. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetol Metab Syndr. 2010;2:55. doi:10.1186/1758-5996-2-5520718958
   PubMed Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi:10.1155/2014/94316224711954
   PubMedGoogle Scholar
• Bonner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol. 1994;24(Suppl 2):S39–S49.
   PubMedGoogle Scholar
• Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286(5):H1597–H1602. doi:10.1152/ajpheart.00026.200415072967
   PubMed Web of Science ®Google Scholar
• Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10. doi:10.1186/1475-2891-7-1018416854
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Silva ACS. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008;4(4):787–803.19065996
   PubMedGoogle Scholar
• Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92(4A):10J–17J. doi:10.1016/s0002-9149(03)00611-8
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1(7):1575–1579.12871293
   PubMed Web of Science ®Google Scholar
• Russo I. The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica. 2012;2012:525374. doi:10.6064/2012/52537424278711
   PubMedGoogle Scholar
• Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972–978.10195925
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556. doi:10.1210/jc.2004-039515181022
   PubMed Web of Science ®Google Scholar
• Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–1614. doi:10.1016/j.biotechadv.2015.08.00126281720
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Ye J, Wang ZQ. Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr Metab Immune Disord Drug Targets. 2008;8(2):78–81. doi:10.2174/18715300878453437618537692
   PubMedGoogle Scholar
• Dong H, Lu FE, Zhao L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med. 2012;18(2):152–160. doi:10.1007/s11655-012-0993-222311412
   PubMedGoogle Scholar
• Heber D. Herbs and atherosclerosis. Curr Atheroscler Rep. 2001;3(1):93–96.11123854
   PubMedGoogle Scholar
• Alzahrani T, Marrat S, Haider A. Management of dyslipidemia in primary care. Can J Cardiol. 2003;19(13):1499–1502.14760440
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia–current therapies and future agents. Expert Opin Pharmacother. 2003;4(11):1901–1938. doi:10.1517/14656566.4.11.190114596646
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–1132. doi:10.1016/j.jacc.2010.05.03420863953
   PubMed Web of Science ®Google Scholar
• Waltenberger B, Mocan A, Šmejkal K, Heiss EH, Atanasov AG. Natural products to counteract the epidemic of cardiovascular and metabolic disorders. Molecules. 2016;21:6. doi:10.3390/molecules21060807
   Web of Science ®Google Scholar
• Ríos JL, Francini F, Schinella GR. Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 2015;81(12/13):975–994. doi:10.1055/s-0035-154613126132858
   PubMedGoogle Scholar
• Lacroix IM, Li-Chan EC. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes. Mol Nutr Food Res. 2014;58(1):61–78. doi:10.1002/mnfr.20130022323943383
   PubMed Web of Science ®Google Scholar
• Hung HY, Qian K, Morris-Natschke SL, Hsu CS, Lee KH. Recent discovery of plant-derived anti-diabetic natural products. Nat Prod Rep. 2012;29(5):580–606. doi:10.1039/c2np00074a22491825
   PubMed Web of Science ®Google Scholar
• Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev. 2009;29(5):767–820. doi:10.1002/med.2015619378317
   PubMed Web of Science ®Google Scholar
• Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J. Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: a literature review. Adv Ther. 2003;20(1):50–78.12772818
   PubMed Web of Science ®Google Scholar
• Vasanthi HR, ShriShriMal N, Das DK. Phytochemicals from plants to combat cardiovascular disease. Curr Med Chem. 2012;19(14):2242–2251.22414106
   PubMed Web of Science ®Google Scholar
• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Res. 2000;49(10):497–505. doi:10.1007/s000110050622
   PubMed Web of Science ®Google Scholar
• Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol. 2003;3(2):186–191.12681242
   PubMed Web of Science ®Google Scholar
• Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812(8):1007–1022. doi:10.1016/j.bbadis.2011.02.01421382489
   PubMed Web of Science ®Google Scholar
• Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201–2207. doi:10.1210/en.2003-028812746275
   PubMed Web of Science ®Google Scholar
• Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 2003;88(6):2412–2421. doi:10.1210/jc.2003-03043512788836
   PubMedGoogle Scholar
• Francis GA, Annicotte JS, Auwerx J. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol. 2003;285(1):H1–H9. doi:10.1152/ajpheart.01118.200212623780
   PubMedGoogle Scholar
• Miller AR, Etgen GJ. Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Expert Opin Investig Drugs. 2003;12(9):1489–1500. doi:10.1517/13543784.12.9.1489
   PubMed Web of Science ®Google Scholar
• Huang TH, Kota BP, Razmovski V, Roufogalis BD. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol. 2005;96(1):3–14. doi:10.1111/j.1742-7843.2005.pto960102.x15667590
   PubMedGoogle Scholar
• Jaradat MS, Noonan DJ, Wu B, Avery MA, Feller DR. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists. Planta Med. 2002;68(8):667–671. doi:10.1055/s-2002-3378512221584
   PubMedGoogle Scholar
• Yoon M, Lee H, Jeong S, et al. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng. Br J Pharmacol. 2003;138(7):1295–1302. doi:10.1038/sj.bjp.070516912711630
   PubMedGoogle Scholar
• Yang Y, Wu T, He K, Fu ZG. Effect of aerobic exercise and ginsenosides on lipid metabolism in diet-induced hyperlipidemia mice. Zhongguo Yao Li Xue Bao. 1999;20(6):563–565.10678155
   PubMed Web of Science ®Google Scholar
• Kim SH, Park KS. Effects of panax ginseng extract on lipid metabolism in humans. Pharmacological Res. 2003;48(5):511–513.
   PubMed Web of Science ®Google Scholar
• Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CW. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem. 2003;278(2):962–967. doi:10.1074/jbc.M20948320012421816
   PubMed Web of Science ®Google Scholar
• Shi Y. Orphan nuclear receptors in drug discovery. Drug Discov Today. 2007;12(11–12):440–445. doi:10.1016/j.drudis.2007.04.00617532527
   PubMedGoogle Scholar
• Bramlett KS, Houck KA, Borchert KM, et al. A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003;307(1):291–296. doi:10.1124/jpet.103.05285212893846
   PubMedGoogle Scholar
• Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol. 2004;40(3):539–551. doi:10.1016/j.jhep.2003.11.00615123373
   PubMed Web of Science ®Google Scholar
• Urizar NL, Moore DD. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr. 2003;23:303–313. doi:10.1146/annurev.nutr.23.011702.07310212626688
   PubMed Web of Science ®Google Scholar
• Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine. 2017;12:2689. doi:10.2147/IJN.S13197328435252
   PubMed Web of Science ®Google Scholar
• Rachmawati H, SORAYA I, Kurniati N, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm. 2016;84(1):131–140. doi:10.3797/scipharm.ISP.2015.0527110504
   PubMedGoogle Scholar
• Taghipour YD, Bahramsoltani R, Marques AM, et al. A systematic review of nano formulation of natural products for the treatment of inflammatory bowel disease: drug delivery and pharmacological targets. DARU J Pharm Sci. 2018;26(2):229–239.
   Web of Science ®Google Scholar
• Soetikno V, Sari FR, Veeraveedu PT, et al. Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond). 2011;8(1):35. doi:10.1186/1743-7075-8-3521663638
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr. 2010;30:173–199. doi:10.1146/annurev.nutr.012809.10475520420526
   PubMed Web of Science ®Google Scholar
• Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995;270(42):24995–25000. doi:10.1074/jbc.270.42.249957559628
   PubMed Web of Science ®Google Scholar
• Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G20–G30. doi:10.1152/ajpgi.00474.200212660143
   PubMed Web of Science ®Google Scholar
• Gonzalez-Castejon M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: a review. Pharmacological Res. 2011;64(5):438–455.
   PubMed Web of Science ®Google Scholar
• Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787–809. doi:10.1016/j.bcp.2007.08.01617900536
   PubMed Web of Science ®Google Scholar
• Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631–1652. doi:10.1007/s00018-008-7452-418324353
   PubMed Web of Science ®Google Scholar
• Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86–92.696348
   PubMedGoogle Scholar
• Ernest U, Chen H-Y, Xu M-J, et al. Anti-cancerous potential of polyphenol-loaded polymeric nanotherapeutics. Molecules. 2018;23(11):2787. doi:10.3390/molecules23112787
   PubMed Web of Science ®Google Scholar
• Hajialyani M, Tewari D, Sobarzo-Sánchez E, Nabavi SM, Farzaei MH, Abdollahi M. Natural product-based nanomedicines for wound healing purposes: therapeutic targets and drug delivery systems. Int J Nanomedicine. 2018;13:5023–5043. doi:10.2147/IJN.S17407230214204
   PubMed Web of Science ®Google Scholar
• Tong F, Chai R, Jiang H, Dong B. In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles. Int J Nanomedicine. 2018;13:1945. doi:10.2147/IJN.S17762729662310
   PubMed Web of Science ®Google Scholar
• Joshi RP, Negi G, Kumar A, et al. SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection. Nanomed. 2013;9(6):776–785. doi:10.1016/j.nano.2013.01.001
   PubMed Web of Science ®Google Scholar
• Grama CN, Suryanarayana P, Patil MA, et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS One. 2013;8(10):e78217. doi:10.1371/journal.pone.007821724155984
   PubMed Web of Science ®Google Scholar
• El-Far YM, Zakaria MM, Gabr MM, El Gayar AM, Eissa LA, El-Sherbiny IM. Nanoformulated natural therapeutics for management of streptozotocin-induced diabetes: potential use of curcumin nanoformulation. Nanomedicine. 2017;12(14):1689–1711. doi:10.2217/nnm-2017-010628635562
   PubMed Web of Science ®Google Scholar
• Devadasu VR, Wadsworth RM, Kumar MR. Protective effects of nanoparticulate coenzyme Q 10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: a possible remedy to diabetic complications. Drug Deliv Transl Res. 2011;1(6):448–455. doi:10.1007/s13346-011-0041-325786365
   PubMedGoogle Scholar
• Rachmawati H, Soraya IS, Kurniati NF, Rahma A. In vitro study on antihypertensive and antihypercholesterolemic effects of a curcumin nanoemulsion. Sci Pharm. 2016;84(1):131–140. doi:10.3797/scipharm.ISP.2015.0527110504
   PubMedGoogle Scholar
• Jia T, Rao J, Zou L, et al. Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia. Front Neurosci. 2018;11:755. doi:10.3389/fnins.2017.0075529422835
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Z, Wang J, et al. Encapsulation of curcumin nanoparticles with MMP9-responsive and thermos-sensitive hydrogel improves diabetic wound healing. ACS Appl Mater Interfaces. 2018;10(19):16315–16326. doi:10.1021/acsami.8b0386829687718
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1–2):71–80. doi:10.1016/j.drudis.2011.09.00921959306
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan CS. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des. 2013;19(11):1994–2010.23116309
   PubMed Web of Science ®Google Scholar
• Melgar-Lalanne G, Hernández-Álvarez AJ, Jiménez-Fernández M, Azuara E. Oleoresins from capsicum spp.: extraction methods and bioactivity. Food Bioproc Tech. 2017;10(1):51–76. doi:10.1007/s11947-016-1793-z
   Web of Science ®Google Scholar
• Dwivedi V, Shrivastava R, Hussain S, Ganguly C, Bharadwaj M. Cytotoxic potential of Indian spices (extracts) against esophageal squamous carcinoma cells. Asian Pac J Cancer Prev. 2011;12(8):2069–2073.22292653
   PubMedGoogle Scholar
• Allemand A, Leonardi BF, Zimmer AR, Moreno S, Romao PRT, Gosmann G. Red pepper (Capsicum baccatum) extracts present anti-inflammatory effects in vivo and inhibit the production of TNF-α and NO in vitro. J Med Food. 2016;19(8):759–767. doi:10.1089/jmf.2015.010127533650
   PubMedGoogle Scholar
• Kim J-Y, Lee M-S, Jung S, et al. Anti-obesity efficacy of nanoemulsion oleoresin capsicum in obese rats fed a high-fat diet. Int J Nanomedicine. 2014;9:301. doi:10.2147/IJN.S5241424403834
   PubMed Web of Science ®Google Scholar
• Lee M-S, Jung S, Shin Y, et al. Lipolytic efficacy of alginate double-layer nanoemulsion containing oleoresin capsicum in differentiated 3T3-L1 adipocytes. Food Nutr Res. 2017;61(1):1339553. doi:10.1080/16546628.2017.133955328747860
   PubMedGoogle Scholar
• Wang N, Tan H-Y, Li L, Yuen M-F, Feng Y. Berberine and coptidis rhizoma as potential anticancer agents: recent updates and future perspectives. J Ethnopharmacol. 2015;176:35–48. doi:10.1016/j.jep.2015.10.02826494507
   PubMed Web of Science ®Google Scholar
• Bao J, Huang B, Zou L, et al. Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents. PLoS One. 2015;10(9):e0139298. doi:10.1371/journal.pone.013929826421434
   PubMedGoogle Scholar
• Li M, Zhang M, Zhang Z-L, et al. Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB. Oncol Res Featuring Preclinical Clin Cancer Ther. 2017;25(2):233–239. doi:10.3727/096504016X14742891049073
   Google Scholar
• Yang J, Yin J, Gao H, et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med. 2012;2012. doi:10.1155/2012/363845
   Web of Science ®Google Scholar
• Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–2264. doi:10.2337/db06-000616873688
   PubMed Web of Science ®Google Scholar
• Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Espinel-Bermúdez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013;11(5):366–369. doi:10.1089/met.2012.018323808999
   PubMedGoogle Scholar
• Xue M, Yang M-X, Zhang W, et al. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine. 2013;8:4677. doi:10.2147/IJN.S3746524353417
   PubMed Web of Science ®Google Scholar
• Kapoor R, Singh S, Tripathi M, Bhatnagar P, Kakkar P, Gupta KC. O-hexadecyl-dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes. PLoS One. 2014;9(2):e89124. doi:10.1371/journal.pone.008912424586539
   PubMed Web of Science ®Google Scholar
• Ochin CC, Garelnabi M. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells. Cardiovasc Hematol Disord Drug Targets. 2018;18(1):61–70. doi:10.2174/1871529X1866618020113034029422010
   PubMedGoogle Scholar
• Cavia-Saiz M, Busto MD, Pilar-Izquierdo MC, Ortega N, Perez-Mateos M, Muñiz P. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study. J Sci Food Agric. 2010;90(7):1238–1244. doi:10.1002/jsfa.395920394007
   PubMed Web of Science ®Google Scholar
• Ortiz-Andrade RR, Sánchez-Salgado JC, Navarrete-Vázquez G, et al. Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation. Diabetes Metab Syndr Obes. 2008;10(11):1097–1104. doi:10.1111/j.1463-1326.2008.00869.x
   Google Scholar
• Prabu SM, Renugadevi J, Shagirtha K. In vivo and in vitro antioxidative efficacy of naringenin on cadmium-induced toxicity in rats. Res Rev. 2019;3(3):9–16.
   Google Scholar
• Scalbert A, Rémésy C, Morand C, Jiménez L, Manach C. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727–747. doi:10.1093/ajcn/79.5.72715113710
   PubMedGoogle Scholar
• Maity S, Mukhopadhyay P, Kundu PP, Chakraborti AS. Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals—an in vitro and in vivo approach. Carbohydr Polym. 2017;170:124–132. doi:10.1016/j.carbpol.2017.04.06628521977
   PubMed Web of Science ®Google Scholar
• Hashemzaei M, Delarami Far A, Yari A, et al. Anticancer and apoptosis‑inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017;38(2):819–828. doi:10.3892/or.2017.576628677813
   PubMed Web of Science ®Google Scholar
• Leiherer A, Stoemmer K, Muendlein A, et al. Quercetin impacts expression of metabolism-and obesity-associated genes in SGBS adipocytes. Nutrients. 2016;8(5):282. doi:10.3390/nu8050282
   PubMed Web of Science ®Google Scholar
• Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity. 2008;16(9):2081–2087. doi:10.1038/oby.2008.31518551111
   PubMed Web of Science ®Google Scholar
• Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets. 2009;8(1):2–10.19275687
   PubMedGoogle Scholar
• Mitjavila M, Moreno J. The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases. Biochem Pharmacol. 2012;84(9):1113–1122. doi:10.1016/j.bcp.2012.07.01722858365
   PubMedGoogle Scholar
• Abdollahi M, Tabatabaei-Malazy O, Larijani B. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans islets. J Pharm Pharm Sci. 2012;15(3):447–466. doi:10.18433/J32W2923148894
   PubMedGoogle Scholar
• Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr Metab Cardiovasc Dis. 2013;23(5):403–409. doi:10.1016/j.numecd.2011.08.01022118955
   PubMed Web of Science ®Google Scholar
• Tong F, Liu S, Yan B, Li X, Ruan S, Yang S. Quercetin nanoparticle complex attenuated diabetic nephropathy via regulating the expression level of ICAM-1 on endothelium. Int J Nanomedicine. 2017;12:7799. doi:10.2147/IJN.S14697829123394
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Maity S, Mandal S, Chakraborti AS, Prajapati A, Kundu P. Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment. Carbohydr Polym. 2018;182:42–51. doi:10.1016/j.carbpol.2017.10.09829279124
   PubMed Web of Science ®Google Scholar
• Schwingel TE, Klein CP, Nicoletti NF, et al. Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(9):837–848. doi:10.1007/s00210-014-0994-024908156
   PubMed Web of Science ®Google Scholar
• Chitkara D, Nikalaje SK, Mittal A, Chand M, Kumar N. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv Transl Res. 2012;2(2):112–123. doi:10.1007/s13346-012-0063-525786720
   PubMed Web of Science ®Google Scholar
• Alam MM, Abdullah K, Singh BR, Naqvi AH, Naseem I. Ameliorative effect of quercetin nanorods on diabetic mice: mechanistic and therapeutic strategies. RSC Adv. 2016;6(60):55092–55103. doi:10.1039/C6RA04821H
   Web of Science ®Google Scholar
• Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang C-J. Emodin, a protein tyrosine kinase inhibitor from polygonum cuspidatum. J Nat Prod. 1992;55(5):696–698.1517743
   PubMed Web of Science ®Google Scholar
• Dong X, Fu J, Yin X, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytotherapy Research. 2016;30(8):1207–1218. doi:10.1002/ptr.563127188216
   PubMed Web of Science ®Google Scholar
• Li L, Sheng X, Zhao S, et al. Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia. Purinergic Signal. 2017;13(4):559–568. doi:10.1007/s11302-017-9583-228840511
   PubMed Web of Science ®Google Scholar
• Lu K, Xie S, Han S, et al. Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. J Transl Med. 2014;12(1):72. doi:10.1186/1479-5876-12-7224641917
   PubMedGoogle Scholar
• Patel K, Gadewar M, Tripathi R. Pharmacological and analytical aspects of gymnemic acid: a concise report. Asian Pac J Trop Dis. 2012;2(5):414–416. doi:10.1016/S2222-1808(12)60090-5
   Google Scholar
• Ankit S, Chetan S, Aneja KR, Rakesh P. Gymnema sylvestre (Gurmar): a review. Der Pharmacia Lettre. 2010;2(1):275–284.
   Google Scholar
• Ravichandran R. Studies on gymnemic acids nanoparticulate formulations against diabetes mellitus. Int J Biomed Clin Eng. 2012;1(2):1–12. doi:10.4018/IJBCE
   Google Scholar
• Waisundara VY, Hsu A, Tan BK, Huang D. Baicalin improves antioxidant status of streptozotocin-induced diabetic wistar rats. J Agric Food Chem. 2009;57(10):4096–4102. doi:10.1021/jf802853919364111
   PubMed Web of Science ®Google Scholar
• Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 2017;131:68–80. doi:10.1016/j.ejmech.2017.03.00428288320
   PubMed Web of Science ®Google Scholar
• Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769–3779. doi:10.2147/IJN.S5157824124365
   PubMed Web of Science ®Google Scholar
• Shi F, Wei Z, Zhao Y, Xu X. Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects. Pharmacogn Mag. 2016;12(47):198. doi:10.4103/0973-1296.18634727601850
   PubMed Web of Science ®Google Scholar
• Xiong F, Wang H, Cheng J, Zhu J. Determination of scutellarin in mouse plasma and different tissues by high-performance liquid chromatography. J Chromatogr B. 2006;835(1–2):114–118. doi:10.1016/j.jchromb.2006.02.041
   PubMed Web of Science ®Google Scholar
• Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015;2015. doi:10.1155/2015/680756
   Web of Science ®Google Scholar
• Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015;2015:680756. doi:10.1155/2015/68075625866802
   PubMedGoogle Scholar
• Wang J, Tan J, Luo J, et al. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. J Nanobiotechnology. 2017;15(1):18. doi:10.1186/s12951-017-0305-228249594
   PubMedGoogle Scholar
• Matos M, Gutiérrez G, Coca J, Pazos C. Preparation of water-in-oil-in-water (W1/O/W2) double emulsions containing trans-resveratrol. Colloids Surf A Physicochem Eng Asp. 2014;442:69–79. doi:10.1016/j.colsurfa.2013.05.065
   Web of Science ®Google Scholar
• Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. Int J Pharm. 2015;479(2):282–290. doi:10.1016/j.ijpharm.2015.01.00325572692
   PubMed Web of Science ®Google Scholar
• Bremer AA. Resveratrol use in metabolic syndrome. Metab Syndr Relat Disord. 2014;12(10):493–495. doi:10.1089/met.2014.150525229675
   PubMedGoogle Scholar
• Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacological Res. 2015;91:104–114. doi:10.1016/j.phrs.2014.10.004
   PubMed Web of Science ®Google Scholar
• Juhasz B, Mukherjee S, Das DK. Hormetic response of resveratrol against cardioprotection. Exp Clin Cardiol. 2010;15(4):e134.21264071
   PubMedGoogle Scholar
• Juhasz B, Das DK, Kertesz A, Juhasz A, Gesztelyi R, Varga B. Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, longevinex.[corrected]. Mol Cell Biochem. 2011;348(1–2):199–203. doi:10.1007/s11010-010-0615-221052791
   PubMed Web of Science ®Google Scholar
• Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol. 2010;11(8):810–818.20874691
   PubMed Web of Science ®Google Scholar
• Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12(10):497–501. doi:10.1089/met.2014.008225137036
   PubMed Web of Science ®Google Scholar
• Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus–systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147–159. doi:10.1002/mnfr.20140017325138371
   PubMed Web of Science ®Google Scholar
• Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012;113(3):752–759. doi:10.1002/jcb.2343122065601
   PubMedGoogle Scholar
• Yücel Ç, Karatoprak GŞ, Aktaş Y. Nanoliposomal resveratrol as a novel approach to treatment of diabetes mellitus. J Nanosci Nanotechnol. 2018;18(6):3856–3864. doi:10.1166/jnn.2018.1524729442719
   PubMed Web of Science ®Google Scholar
• Shahraki A, Bahadorikhalili S, Hashemzaei M, et al. Resveratrol nano-capsule as an efficient tool for blood pressure regulation: a study on metabolic syndrome induced mice. Biosci Biotechnol Res Commun. 2017;10(4):623–630. doi:10.21786/bbrc/10.4/4
   Google Scholar
• Hoh CS, Boocock DJ, Marczylo TH, et al. Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle (Silybum marianum), in human plasma by high-performance liquid chromatography and identification of possible metabolites. J Agric Food Chem. 2007;55(7):2532–2535. doi:10.1021/jf063156c17355141
   PubMedGoogle Scholar
• Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review. Phytother Res. 2018;32(10):1933–1949. doi:10.1002/ptr.615330015401
   PubMed Web of Science ®Google Scholar
• Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035–2063. doi:10.2165/00003495-200161140-0000311735632
   PubMed Web of Science ®Google Scholar
• Huseini HF, Larijani B, Heshmat R, et al. The efficacy of silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20(12):1036–1039. doi:10.1002/ptr.198817072885
   PubMed Web of Science ®Google Scholar
• Das S, Roy P, Pal R, Auddy RG, Chakraborti AS, Mukherjee A. Engineered silybin nanoparticles educe efficient control in experimental diabetes. PLoS One. 2014;9(7):e101818. doi:10.1371/journal.pone.010181824991800
   PubMed Web of Science ®Google Scholar
• Pereira M, Siba IP, Chioca LR, et al. Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1636–1644. doi:10.1016/j.pnpbp.2011.06.00221689712
   PubMed Web of Science ®Google Scholar
• Sun GB, Qin M, Ye JX, et al. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol. 2013;271(1):114–126. doi:10.1016/j.taap.2013.04.01523639522
   PubMed Web of Science ®Google Scholar
• Fernandez SP, Nguyen M, Yow TT, et al. The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice. Neurochem Res. 2009;34(10):1867–1875. doi:10.1007/s11064-009-9969-919387830
   PubMed Web of Science ®Google Scholar
• Ahangarpour A, Oroojan AA, Khorsandi L, Kouchak M, Badavi M. Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse. Oxid Med Cell Longev. 2018;2018. doi:10.1155/2018/7496936
   PubMed Web of Science ®Google Scholar
• Goyal SK, Samsher GRK, Goyal RK. Stevia (Stevia rebaudiana) a bio-sweetener: a review. Int J Food Sci Nutr. 2010;61(1):1–10. doi:10.3109/0963748090319304919961353
   PubMed Web of Science ®Google Scholar
• Kujur RS, Singh V, Ram M, et al. Antidiabetic activity and phytochemical screening of crude extract of stevia rebaudiana in alloxan-induced diabetic rats. Pharmacognosy Res. 2010;2(4):258–263. doi:10.4103/0974-8490.6912821808578
   PubMedGoogle Scholar
• Barwal I, Sood A, Sharma M, Singh B, Yadav SC. Development of stevioside pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine. Colloids Surf B. 2013;101:510–516. doi:10.1016/j.colsurfb.2012.07.005
   PubMed Web of Science ®Google Scholar
• Fang EF, Ng TB. Chapter 28 - bitter gourd (momordica charantia) oils In: Preedy VR, editor. Essential Oils in Food Preservation, Flavor and Safety. San Diego: Academic Press; 2016:253–257.
   Google Scholar
• Paul D, Dey TK, Mukherjee S, Ghosh M, Dhar P. Comparative prophylactic effects of α-eleostearic acid rich nano and conventional emulsions in induced diabetic rats. J Food Sci Technol. 2014;51(9):1724–1736. doi:10.1007/s13197-014-1257-225190828
   PubMed Web of Science ®Google Scholar
• Balarini CM, Braga VA. New translational insights on metabolic syndrome: obesity, hypertension, diabetes and beyond. Front Physiol. 2016;7:229. doi:10.3389/fphys.2016.0022927375501
   PubMedGoogle Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1–20.11166403
   PubMed Web of Science ®Google Scholar